essay
few Emma
CFOAnnualReportReviewforyear2011andyear2012.xlsxSheet1
| Current Ratio | ||
| Items | 2012 | 2011 |
| Total current assets | 46,116 | 54,316 |
| Total current liabilities | 24,262 | 22,811 |
| Current ratio | 1.9007 | 2 |
Sheet2
| John Jonssone | |||||||||||||
| Balance Sheet | |||||||||||||
| As at January 1, 2012 | |||||||||||||
| Assets | Liabilities | ||||||||||||
| Current Assets | Current liabilities | ||||||||||||
| Cash and cash equivalents(Notes 1 and 2) | 39453 | Loans and notes payable (Note 7) | 11334 | ||||||||||
| Marketable securities(Notes 1 and 2) | 13897 | Accounts payable | 11556 | ||||||||||
| Account receivable trade | 21890 | Accrued liabilities | 11907 | ||||||||||
| Inventories(Notes 1 and 3) | 13780 | Accrued rebates, returns and promotions | 5606 | ||||||||||
| Deferred taxes on income(Note 8) | 5695 | Accrued compensation and employee related obligations | 11081 | ||||||||||
| Prepaid expenses and other receivables | 5717 | Accrued taxes on income | 7190 | ||||||||||
| Total current assets | 100432 | Total current liabilities | 58674 | ||||||||||
| Fixed Assets | |||||||||||||
| Property, plant and equipment, net (Notes 1 and 4) | 30836 | Long term liabilities | |||||||||||
| Intangible assets, net (Notes 1 and 5) | 46890 | Long-term debt (Note 7) | 24458 | ||||||||||
| Goodwill (Notes 1 and 5) | 38562 | Deferred taxes on income (Note 8) | 4936 | ||||||||||
| Deferred taxes on income (Note 8) | 11081 | Employee related obligations (Notes 9 and 10) | 17435 | ||||||||||
| Other assets | 7190 | Other liabilities | 19183 | ||||||||||
| Total assets | 234991 | Total liabilities | 124686 | ||||||||||
| Assets | 2012 | 2011 | |||||||||||
| Cash and cash equivalents (Notes 1 and 2) | $14,911 | 24,542 | |||||||||||
| Marketable securities (Notes 1 and 2) | 6,178 | 7,719 | |||||||||||
| Accounts receivable trade, less allowances for doubtful accounts $466 (2011, $361) | 11,309 | 10,581 | |||||||||||
| Inventories (Notes 1 and 3) | 7,495 | 6,285 | |||||||||||
| Deferred taxes on income (Note 8) | 3,139 | 2,556 | |||||||||||
| Prepaid expenses and other receivables | 3,084 | 2,633 | |||||||||||
| Total current assets | 46,116 | 54,316 | |||||||||||
| Current Liabilities | |||||||||||||
| Loans and notes payable (Note 7) | $4,676 | 6,658 | |||||||||||
| Accounts payable | 5,831 | 5,725 | |||||||||||
| Accrued liabilities | 7,299 | 4,608 | |||||||||||
| Accrued rebates, returns and promotions | 2,969 | 2,637 | |||||||||||
| Accrued compensation and employee related obligations | 2,423 | 2,329 | |||||||||||
| Accrued taxes on income | 1,064 | 854 | |||||||||||
| Total current liabilities | 24,262 | 22,811 | |||||||||||
| (Dollars in Millions Except Per Share | First | Second | Third | Fourth | First | Second | Third | Fourth | |||||
| Data) | Quarter(1) | Quarter(2) | Quarter(3) | Quarter(4) | Quarter(1) | Quarter(6) | Quarter(7) | Quarter(8) | |||||
| Segment sales to customers | |||||||||||||
| Consumer | 3,595 | 3,619 | 3,581 | 3,652 | 3,682 | 3,793 | 3,740 | 3,668 | |||||
| Pharmaceutical | 6,133 | 6,291 | 6,402 | 6,525 | 6,059 | 6,233 | 5,982 | 6,094 | |||||
| Med Devices & Diagnostics | 6,411 | 6,565 | 7,069 | 7,381 | 6,432 | 6,571 | 6,283 | 6,493 | |||||
| Total sales | 16,139 | 16,475 | 17,052 | 17,558 | 16,173 | 16,597 | 16,005 | 16,255 | |||||
| Gross profit | 11,224 | 11,332 | 11,455 | 11,555 | 11,395 | 11,425 | 10,933 | 10,917 | |||||
| Earnings before provision for taxes on | |||||||||||||
| income | 5,045 | 2,035 | 3,595 | 3,100 | 4,510 | 3,422 | 4,111 | 318 | |||||
| Net earnings attributable to Johnson & | |||||||||||||
| Johnson | 3,910 | 1,408 | 2,968 | 2,567 | 3,476 | 2,776 | 3,202 | 218 | |||||
| Basic net earnings per share attributable | |||||||||||||
| to Johnson & Johnson | $1.43 | 0.51 | 1.08 | 0.93 | 1.27 | 1 | 1.17 | 0.08 | |||||
| Diluted net earnings per share | |||||||||||||
| attributable to Johnson & Johnson | $1.41 | 0.5 | 1.05 | 0.91 | 1.25 | 1 | 1.15 | 0.08 |
Assets
Assets Cash and cash equivalents (Notes 1 and 2) Marketable securities (Notes 1 and 2) Accounts receivable trade, less allowances for doubtful accounts $466 (2011, $361) Inventories (Notes 1 and 3) Deferred taxes on income (Note 8) Prepaid expenses and other receivables Total current assets 2012 14911 6178 11309 7495 3139 3084 46116 Assets Cash and cash equivalents (Notes 1 and 2) Marketable securities (Notes 1 and 2) Accounts receivable trade, less allowances for doubtful accounts $466 (2011, $361) Inventories (Notes 1 and 3) Deferred taxes on income (Note 8) Prepaid expenses and other receivables Total current assets 2011 24542 7719 10581 6285 2556 2633 54316Amount
Current Liabilities Loans and notes payable (Note 7) Accounts payable Accrued liabilities Accrued rebates, returns and promotions Accrued compensation and employee related obligations Accrued taxes on income Total current liabilities 4676 5831 7299 2969 2423 1064 24262 Current Liabilities Loans and notes payable (Note 7) Accounts payable Accrued liabilities Accrued rebates, returns and promotions Accrued compensation and employee related obligations Accrued taxes on income Total current liabilities 6658 5725 4608 2637 2329 854 22811 (Dollars in Millions Except Per Share Data) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson (Dollars in Millions Except Per Share Data) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson (Dollars in Millions Except Per Share Data) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson First Quarter(1) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson 3595 6133 6411 16139 11224 5045 3910 1.43 1.41 Second Quarter(2) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson 3619 6291 6565 16475 11332 2035 1408 0.51 0.5 Third Quarter(3) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson 3581 6402 7069 17052 11455 3595 2968 1.08 1.05 Fourth Quarter(4) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson 3652 6525 7381 17558 11555 3100 2567 0.93 0.91 First Quarter(1) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson 3682 6059 6432 16173 11395 4510 3476 1.27 1.25 Second Quarter(6) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson 3793 6233 6571 16597 11425 3422 2776 1.01 1 Third Quarter(7) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson 3740 5982 6283 16005 10933 4111 3202 1.17 1.1499999999999999 Fourth Quarter(8) Segment sales to customers Consumer Pharmaceutical Med Devices & Diagnostics Total sales Gross profit Earnings before provision for taxes on income Net earnings attributable to Johnson & Johnson Basic net earnings per share attributable to Johnson & Johnson Diluted net earnings per share attributable to Johnson & Johnson 3668 6094 6493 16255 10917 318 218 0.08 0.08
